Empagliflozin and hydralazine-isosorbide dinitrate combination therapy improves outcomes in Black patients with heart failure
Empa + H-ISDN offered superior benefits in Black patients with HFrEF, possibly by reducing oxidative stress and enhancing nitric oxide (NO) bioavailability.
Authors
- Padmamalini Baskaran (ORCID: https://orcid.org/0000-0001-8851-1486)
- La’Marcus T. Wingate (ORCID: https://orcid.org/0000-0003-4312-4532)
- Mohammed Aldhaeefi (ORCID: https://orcid.org/0000-0002-5985-9149)
- Anise Asaadi (ORCID: https://orcid.org/0000-0003-2852-8352)
- Dhakrit Rungkitwattanakul (ORCID: https://orcid.org/0000-0003-2674-342X)
- Morgan Jones (ORCID: https://orcid.org/0009-0001-0493-0104)
- E King
Publication Details
- Journal
- International Journal of Clinical Pharmacology and Therapeutics
- Published
- 2025-09-01
- DOI
- https://doi.org/10.5414/cp204854
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00